Skip to main content

Advertisement

Table 3 Type specific prevalence of oncogenic HPV infection in women with (1) ASC-H/HSIL cytology * , (2) histologically-confirmed grade CIN 2 and (3) ≥ CIN 3

From: Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand

  ASC-H/HSIL cytology*(N=594) CIN 2(N=152) ≥ CIN 3†‡(N=223)
HR HPV type n % 95% CI n % 95% CI n % 95% CI
16 262 44.1 (40.1 - 48.2) 70 46.1 (37.9 - 54.3) 122 54.7 (47.9 - 61.4)
52 β 100 16.8 (13.9 - 20.1) 24 15.8 (10.4 - 22.6) 47 21.1 (15.9 - 27.0)
31 90 15.2 (12.4 - 18.3) 37 24.3 (17.8 - 32.0) 27 12.1 (8.1 - 17.1)
33 70 11.8 (9.3 - 14.7) 26 17.1 (11.5 - 24.0) 21 9.4 (5.9 - 14.0)
18 67 11.3 (8.8 - 14.1) 16 10.5 (6.1 - 16.5) 32 14.3 (10.0 - 19.6)
58 60 10.1 (7.8 - 12.8) 21 13.8 (8.8 - 20.3) 21 9.4 (5.9 - 14.0)
51 54 9.1 (6.9 - 11.7) 12 7.9 (4.1 - 13.4) 24 10.8 (7.0 - 15.6)
39 39 6.6 (4.7 - 8.9) 14 9.2 (5.1 - 15.0) 12 5.4 (2.8 - 9.2)
45 29 4.9 (3.3 - 6.9) 4 2.6 (0.7 - 6.6) 13 5.8 (3.1 - 9.8)
59 26 4.4 (2.9 - 6.3) 5 3.3 (1.1 - 7.5) 12 5.4 (2.8 - 9.2)
35 25 4.2 (2.7 - 6.2) 12 7.9 (4.1 - 13.4) 5 2.2 (0.7 - 5.2)
56 20 3.4 (2.1 - 5.2) 3 2.0 (0.4 - 5.7) 7 3.1 (1.3 - 6.4)
68 14 2.4 (1.3 - 3.9) 4 2.6 (0.7 - 6.6) 4 1.8 (0.5 - 4.5)
16 and/or 18 314 52.9 (48.8 - 56.9) 80 52.6 (44.4 - 60.8) 148 66.4 (59.8 - 72.5)
16 and/or 18 (alone) 112 18.9 (15.8 - 22.2) 33 21.7 (15.4 - 29.1) 49 22.0 (16.7 - 30.0)
OHR 201 33.8 (30.0 - 37.8) 65 42.8 (34.8 - 51.0) 63 28.3 (22.3 - 34.6)
Single HR HPV 277 46.7 (42.6 - 50.7) 70 46.1 (37.9 - 54.3) 117 52.5 (45.7 - 59.2)
Any HR HPV 515 86.7 (83.7 - 89.3) 145 95.4 (90.7 - 98.1) 211 94.6 (90.1 - 97.2)
  1. * High grade cytology includes high grade squamous intra-epithelial lesions (HSIL), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), atypical glandular cells (AGC), adenocarcinoma in situ (AIS) or invasive cancer.
  2. † Restricted to women with a valid HPV (human papillomavirus) test result.
  3. ‡ Includes histologically confirmed CIN 3, AIS, glandular dysplasia or cervical cancer.
  4. β Test positive for infection with HPV type 52 alone; not validated with linear array testing (see text).